MedTrace Logo

Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With EVT on Long-term Prognosis in Patients With AIS (PPDET)

NCT04916197 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 368

Last updated 2023-12-20

No results posted yet for this study

Summary

Dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Dexmedetomidine prolonged sedation

Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.

DRUG

0.9% saline

An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.

Sponsors & Collaborators

  • Beijing Chao Yang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04916197 on ClinicalTrials.gov